Interpretation of the updated NCCN clinical practice guidelines in oncology: Non-small cell lung cancer (version 5. 2024)
- VernacularTitle:2024年第5版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读
- Author:
Guoqing LUO
1
;
Xiao LU
1
;
Dinghui LI
1
;
Min PENG
2
;
Ning LI
1
;
Qing GENG
1
Author Information
1. Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, P. R. China
2. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
NCCN guidelines;
immunotherapy;
targeted therapy;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(07):955-961
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer-related deaths worldwide, especially non-small cell lung cancer (NSCLC). With the popularization of low-dose CT and the improvement of people’s awareness of physical examinations, the number of detected pulmonary nodules is gradually increasing, and there is a greater demand for standardized diagnostic and treatment guidelines. On April 23, 2024, the National Comprehensive Cancer Network updated its clinical practice guidelines for NSCLC to the version 5. Compared with the version 5 in 2023, the version 5 in 2024 updates focus on diagnostic evaluation, perioperative systemic therapy, treatment of advanced NSCLC, and molecular marker testing, which will be interpreted in this article with the aim of providing the latest guidance and reference for the diagnosis and treatment of lung cancer in China.
